$ZURA Cashflow Statement | Understand Stock

$ZURA

$4.26 -$0.01 (0.29%) After hours

$ZURA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 10 months to Dec 31, 2021
Cash flows from operating activities
Net loss before redeemable noncontrolling interest
Adjustments to reconcile net loss before redeemable noncontrolling interest to net cash used in operating activities
Research and development acquired license
Anti-dilution share issuance compensation
Share-based compensation expense
Change in fair value of note payable
Change in fair value of research and development license consideration liability
Change in fair value of private placement warrants
Income from investments held in the Trust Account
Offering costs associated with warrants
Loss upon issuance of private placement warrants
General and administrative expenses paid by related parties
Depreciation and amortization
Foreign exchange transaction gain
Gain on extinguishment of BAFFX17 liability
Other non-cash items, net
Changes in operating assets and liabilities:
Prepaid expenses
Due to related party
Due form related party
Accounts payable
Accounts payable - related party
Accrued expenses
Prepaid expenses and other current assets
Other assets
Accounts payable and accrued expenses

Net cash used in operating activities
Cash flows from investing activities
Purchase of fixed assets
Purchase of research and development license
Net cash used in investing activities
Cash flows from financing activities
Cash deposited in Trust Account
Proceeds received from note payable
Proceeds from issuance of Ordinary Shares in connection with April 2024 Private Placement, net of $7.2 million of transaction costs
April 2024 Private Placement
Total proceeds from issuance of Ordinary Shares in connection with April 2024 Private Placement, net of $7.2 million of transaction costs
Reimbursement from underwriter
Proceeds from issuance of Pre-Funded Warrants in connection with April 2024 Private Placement
April 2024 Private Placement
April 2023 Private Placement
Total proceeds from issuance of Pre-Funded Warrants in connection with April 2024 Private Placement
Repayment of loan to related party
Proceeds received from initial public offering, gross
ATM transaction costs
At The Market Offering
Total aTM transaction costs
Issuance of Class A Ordinary Shares upon exercise of Pre-Funded Warrants
Proceeds from exercise of stock options
Restricted stock units withheld to pay employee withholding taxes
Settlement of note payable
Payment of deferred transaction costs
Consideration paid for Athanor Agreement
Net cash provided by (used in) financing activities

Net change in cash
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, ending of period
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Offering costs included in accrued expenses
Offering costs paid by related party under promissory note
Deferred underwriting commissions
Fair value adjustment to Class A ordinary shares subject to redemption
Increase in redemption value of Class A common stock subject to possible redemption
Issuance of Class A Ordinary Shares in exchange for private placement warrants
Issuance of shares in conjunction with Athanor agreement
Adjustments to redeemable noncontrolling interest
Accretion of redeemable noncontrolling interest to redemption value
Share-based equity issuance costs
Settlement of research and development license consideration liability
Reclassification of deferred offering costs to additional paid-in capital
Assumption of public and private placement warrants in connection with Business Combination
Reclassification of public warrant liability to equity
Issuance of Call Right to noncontrolling interest
Purchase of property and equipment included in accounts payable and accrued expenses
Conversion of Series A-1 convertible preferred stock for Class A Ordinary Shares
Deemed dividend to redeemable noncontrolling interest
Accrued 2023 Lilly License consideration
Deemed contribution from redeemable noncontrolling interest
Issuance of Class A Ordinary shares for 2023 Lilly License
Extinguishment of noncontrolling interest and redeemable noncontrolling interest

Comments